Editor's Note: Green and red arrows refer to intraday stock price movement.NEW YORK ( TheStreet) -- CHANGE IN RATINGS Assurant ( AIZ) rated new Neutral at Goldman. Company faces meaningful earnings headwinds. Buckeye Technologies ( BKI) downgraded at UBS from Buy to Neutral, UBS said. Valuation call, based on a $28 price target. Amdocs ( DOX) upgraded at Barclays to Overweight from Equal Weight. Amdocs is well positioned to benefit from an improving demand backdrop in its core BSS/OSS arenas, Barclays said. Price target increased to $36 from $31. Brinker ( EAT) upgraded at Morgan Stanley from Underweight to Equal-weight, Morgan Stanley said. $26 price target. Company is improving its margins. ITT Educational ( ESI) downgraded at Morgan Stanley to Underweight, Morgan Stanley said. Valuation call, based on a $55 price target. General Electric ( GE) upgraded at Argus from Hold to Buy, Argus Research said. $26 price target. Industrial business is driving growth. Jetblue ( JBLU) downgraded at Soleil from Buy to Hold, Soleil Securities said. $7 price target. Estimates also cut, to reflect higher fuel prices. Carmax ( KMX) upgraded at Oppenheimer from Perform to Outperform, Oppenheimer said. $41 price target. Estimates also increased, to reflect re-accelerating unit growth. Medtronic ( MDT) upgraded at Goldman from Neutral to Buy, Goldman Sachs said. $45 price target. New management should take aggressive action to improve the company. Microsemi ( MSCC) downgraded at Wells to Market Perform, Wells Fargo said. Company is showing good margin expansion. Myriad Genetics ( MYGN) downgraded at Soleil from Buy to Hold, Soleil Securities said. $20 price target. Valuation call. Nokia ( NOK) upgraded at Morgan Keegan from Underperform to Market Perform, Morgan Keegan said. $11.50 price target. Upcoming analyst meeting could be the next catalyst. Northern Trust ( NTRS) downgraded at Citigroup from Buy to Hold, Citigroup said. $55 price target. Company is not positioned well for the current environment. Rovi ( ROVI) downgraded at Morgan Stanley from Overweight to Equal-weight, Morgan Stanley said. $67 price target. Estimates also cut, given low business visibility. AT&T ( T) downgraded at UBS from Buy to Neutral. $29 price target. Company likely to lose subscribers in the first half of the year.
AT&T estimates, target lowered at Goldman. T estimates were cut through 2012. Company is investing heavily to maintain wireless market share. Neutral rating and new $30 price target. Thoratec ( THOR) downgraded at Baird from Outperform to Neutral, Robert Baird said. $28 price target. Company reduced guidance and could be losing market share. Travelers ( TRV) upgraded at Argus from Hold to Buy, Argus Research said. $65 price target. Company has a strong balance sheet and good earnings momentum.